Cybin Inc. CLXPF Archives - Page 2 of 5

TuesdayJul 06, 2021 9:15 am

Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Featured in Stifel Report; Price Target Raised by C$12, Rated as Spec Buy

CYBN continues to demonstrate good progress with its preclinical activities on its novel drug programs, report observed Stifel also notes selecting indications with large patient pools, an understated market size, and potential for multiple synergies across development and distribution Report incorporates both CYB001 and CYB004 into valuation As Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, continues to develop its multimolecule strategy, people are paying attention. A recent Stifel report raised Cybin’s price target by C$12, up from C$4 to C$15, and maintained the company’s speculative buy rating (https://ibn.fm/HLcxX). “CYBN continues to demonstrate good progress…

MondayJun 28, 2021 11:59 am

QualityStocksNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Announces Annual Financial Results, Business Highlights and Adelia Milestones

Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, today released financial and business highlights for its financial year ended March 31, 2021. “It has been an incredibly busy and successful year for the Cybin team, expanding both our product development capabilities and our drug development programs,” said Doug Drysdale, CEO of Cybin. “The enormous progress that we have made serves to strengthen the foundation of our organization, upon which we plan to build further in the coming 12 months as we continue our clinical research activities. I want to thank the entire Cybin team, our…

FridayJun 25, 2021 10:21 am

QualityStocksNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) to Participate in Fireside Chat at Grizzle Psychedelics Con

Cybin (NEO: CYBN) (OTCQB: CLXPF) is a leading biotechnology company focused on progressing psychedelic therapeutics. The company has announced that its Chief Executive Officer Doug Drysdale will participate in a virtual fireside chat at Grizzle Psychedelics Con on June 28, 2021. The fireside chat is slated to begin at 12:30 p.m. ET and will be webcast live at https://ibn.fm/Ec3zS with an archived version available after the event. To view the full press release, visit https://ibn.fm/qWICg About Cybin Inc. Cybin is a leading biotechnology company focused on progressing psychedelic therapeutics by utilizing proprietary drug discovery platforms, innovative drug delivery systems, novel…

ThursdayJun 24, 2021 3:21 pm

Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Targets Anxiety Disorders in Focus of Proprietary Psychedelic Treatments

Decision represents opportunity to help millions suffering from social, generalized anxiety disorders Global markets will reach an estimated $4 billion this year, with significant growth projected looking forward WHO estimates that 1 in 13 adults globally suffer from anxiety; treatment options have slow onset, undesirable side effects Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, has identified social anxiety disorder, or SAD, and generalized anxiety disorder, or GAD, as the initial target indications for its proprietary psychedelic molecule CYB004 (https://ibn.fm/BQdjY). Collectively, the two global markets will reach an estimated $4 billion this year, with significant…

ThursdayJun 24, 2021 10:02 am

QualityStocksNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Names Former FDA Psychiatry Division Director to Clinical Advisory Board

Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, announced its newest Clinical Advisory Board member: Dr. Thomas Laughren. A former director for the Division of Psychiatry Products, Center for Drug Evaluation and Research at the FDA, Laughren oversaw the review of all psychiatric drug-development activities conducted under Investigational New Drug (“IND”) as well as the review of all New Drug Applications (“NDAs”) and supplements for new psychiatric drug claims. He served for 29 years and received numerous awards for his regulatory accomplishments. "As we study psychedelic medicines, the regulatory pathway ahead is still coming into…

WednesdayJun 23, 2021 1:37 pm

QualityStocksNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Announces Participation at Life Sciences Investor Forum

Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, will be participating in the upcoming Life Sciences Investor Forum, scheduled for June 24, 2021. During the presentation, Cybin’s CEO Doug Drysdale will provide an overview of the company, including key information targeting the forum audience. Drysdale’s presentation is scheduled for 9 a.m. ET; an archived version of the presentation will be available following the event. The Life Sciences Investor Forum is designed to be a live, interactive online event where attendees are invited to ask participating companies questions in real time. To view the full presentation,…

TuesdayJun 22, 2021 10:54 am

QualityStocksNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Completes 51st Pre-Clinical Psychedelic Molecule Study

Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, announced that it has completed its 51st preclinical study; the study is a critical step in the company’s progress in the Investigational New Drug (“IND”) process. The 51st study was an in-vitro and in-vivo evaluation of Cybin’s growing number of psychedelic compounds being designed and evaluated for potential therapeutic applications to treat a number of mental health situations. The announcement noted that, to date, the Cybin research and development team has evaluated more than 50 novel compounds for pharmacokinetic properties, metabolic stability, receptor binding and safety in order…

MondayJun 21, 2021 10:24 am

QualityStocksNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) to Participate at the Emerging Growth Conference

Cybin (NEO: CYBN) (OTCQB: CLXPF) has announced that its CEO Doug Drysdale will be participating at the 2021 Emerging Growth Conference, which is scheduled for June 23, 2021.As part of his participation, Drysdale will be presenting a live webcast featuring Cybin, a biotechnology company focused on progressing psychedelic therapeutics. Drysdale’s presentation is scheduled to begin at 2 p.m. ET. Interested individuals can register to view the Cybin executive’s presentation via the webcast. Following the conference, an archived version of the presentation will be available at www.EmergingGrowth.com. To view the presentation, visit https://ibn.fm/i4DMQ To view the full press release, visit https://ibn.fm/Q64Zb…

ThursdayJun 17, 2021 10:52 am

Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Announces First-Ever Trial to Treat COVID-19 Frontline Clinicians, Unveils EMBARK Model

The study will examine treating symptoms of depression, anxiety, burnout and post-traumatic stress EMBARK is groundbreaking psychotherapy model that integrates leading clinical approaches to promote supportive healing with psychedelic medicine Cybin considers it an honor, duty to support healing processes of doctors, nurses and healthcare professionals, says CEO In the first-ever study of its kind, Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, has announced that it is co-sponsoring a study focused on treating frontline clinicians experiencing COVID-related distress (https://ibn.fm/NvMAo). In addition to co-sponsoring the study, Cybin also announced the development of EMBARK, a groundbreaking…

MondayJun 14, 2021 9:55 am

QualityStocksNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) CEO to Participate at H.C. Wainwright Psychedelics in Psychiatry and Beyond Virtual Conference

Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, will be part of the upcoming H.C. Wainwright Psychedelics in Psychiatry and Beyond conference. The all-virtual conference is slated for June 17, 2021. During the conference, Cybin CEO Doug Drysdale will be presenting on Cybin and its business and strategy, as well as a look at where the company stands today. Cybin’s webcast-on-demand presentation will be available starting at 7 a.m. on the morning of June 17, 2021 and will be available for 90 days. In addition to his presentation about Cybin, Drysdale will also be participating…

Site Search

Company Search

Tag: Cybin Inc. CLXPF